Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
14 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
14 Mar 24
8-K
Other Events
11 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
8-K
Termination of a Material Definitive Agreement
14 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
Results of Operations and Financial Condition
12 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
14 Nov 23
8-K
Departure of Directors or Certain Officers
3 Oct 23
8-K
Other Events
14 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
10 Aug 23
8-K
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
25 Jul 23
8-K
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
17 Jul 23
8-K
June 2023 Larimar Therapeutics Corporate Presentation
1 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Results of Operations and Financial Condition
15 May 23
8-K
Submission of Matters to a Vote of Security Holders
12 May 23
ARS
2022 FY
Annual report to shareholders
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
8-K
Departure of Directors or Certain Officers
6 Apr 23
S-8
Registration of securities for employees
14 Mar 23
S-8
Registration of securities for employees
14 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
14 Mar 23
8-K
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
7 Feb 23
8-K
January 2023 Larimar Therapeutics Corporate Presentation
9 Jan 23
EFFECT
Notice of effectiveness
22 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
S-3
Shelf registration
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
10 Nov 22
8-K
October 2022 Larimar Therapeutics Corporate Presentation
20 Oct 22
8-K
Entry into a Material Definitive Agreement
14 Sep 22
Latest ownership filings
SC 13D/A
Flynn James E
15 Mar 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
26 Feb 24
4
James E Flynn
16 Feb 24
SC 13D/A
Flynn James E
16 Feb 24
SC 13D/A
Flynn James E
15 Feb 24
4
FRANK E THOMAS
15 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
Verition Fund Management LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
4
Gopi Shankar
19 Jan 24
4
Michael Celano
19 Jan 24
4
Russell Clayton
19 Jan 24
4
CAROLE BEN-MAIMON
19 Jan 24
4
Gopi Shankar
8 Dec 23
4
JEFFREY W SHERMAN
5 Oct 23
3
JEFFREY W SHERMAN
5 Oct 23
SC 13G
JANUS HENDERSON GROUP PLC
18 Aug 23
144
Notice of proposed sale of securities
24 Jul 23
4
Russell Clayton
18 Jul 23
3
Russell Clayton
18 Jul 23
4
Michael Celano
18 May 23
4
CAROLE BEN-MAIMON
18 May 23
4
Joseph Truitt
18 May 23
4
James E Flynn
11 May 23
4
Joseph Truitt
11 May 23
4
Thomas Edward Hamilton
11 May 23
4
JONATHAN S LEFF
11 May 23
4
FRANK E THOMAS
11 May 23
SC 13D/A
Flynn James E
17 Mar 23
SC 13G
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13G/A
CHI Advisors LLC
13 Feb 23
4
Gopi Shankar
9 Feb 23
3
Gopi Shankar
9 Feb 23
4
Michael Celano
2 Feb 23
4
CAROLE BEN-MAIMON
2 Feb 23
SC 13G/A
Opaleye Management Inc.
23 Jan 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Nov 22
4
MANAGEMENT COMPANY, L.P. (SERIES C) DEERFIELD
20 Sep 22
3
Initial statement of insider ownership
20 Sep 22